- Welcome and Introduction
- Optimizing Current Management of β-Thalassemia
- Evolving Role of Biologic Therapies for β-Thalassemia
- The Promise of Gene Therapy in β-Thalassemia
- Final Thoughts and Audience Question and Answer Session
Date / Time
Janet L. Kwiatkowski, MD, MSCE
Professor of Pediatrics
Director of Thalassemia Program
Division of Hematology
Children's Hospital of Philadelphia
Jeanne Boudreaux, MD
Associate Professor of Pediatrics
Director of the Comprehensive Thalassemia Program
Clinical Director of Hematology
Aflac Cancer & Blood Disorders Center
Children's Healthcare of Atlanta
Sujit Sheth, MD
Department of Pediatrics
Weill Cornell Medicine
New York, New York
The goal of this activity is to improve the knowledge and competence of learners in using novel curative and noncurative therapeutic options for patients with β-thalassemia.
This program is intended for hematologists and other clinicians involved in the management of patients with β-thalassemia.
Upon completion of this activity, participants should be able to:
- Evaluate the medical need for novel therapeutic strategies for the management of β-thalassemia
- Describe the safety and efficacy evidence for novel approaches to reducing transfusion dependence through the use of erythroid maturation agents
- Explain the mechanism of action of gene therapy as a curative approach to β-thalassemia
- Examine key efficacy and safety data on emerging gene therapy strategies and their potential role in the management of patients with β-thalassemia
- Identify patients with β-thalassemia who are candidates for ongoing clinical trials
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.